预约演示
Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase
临床3期免疫疗法上市批准并购临床结果
Alpine’s lead asset is povetacicept being developed for renal indications and autoimmune cytopenias. Image credit: Shutterstock/Tada Images.
Vertex Pharmaceuticals povetacicepto acquire biotech Alpine Immune Sciences foautoimmune cytopenias growing number of pharma spending big on immunotherapy-focused companies.
Vertex Pharmaceuticalsoper will pay $65 for each VertAlpine Immune Sciences% premium on the US biotech’s stock’s close on 9 April. Rumours of takeover interest surfaced on 10 April via Bloomberg, with the two companies publicly announcing the board-approved acquisition agreement via a press release the same day.
Alpine’s lead asset is povetacicept, a dual agoniVertextwo cytokines – namely B cell activating factor and a proliferation-inducing ligand. The two proteins, called BAFF and APRIL, play a key role in the development of autoimmune diseases.
The biotech is developipovetacicept also dubbed ALPN-303, in renal indicationsB cell activating factoras. Emerging with high promise is the drug’s efficacy in treatiBAFFmmunoAPRILlin A nephropathy (IgAN), an autoimmune autoimmune diseases
Vertex’s CEO Reshma Kewalramani says povetacicepALPN-303potential best-in-class treautoimmune cytopeniasimmunoglobulin A nephropathy (IgAN)autoimmune kidney disease
Innate Pharma plans IND of ADC candidate after positive preclinical data
Innate Pharmarma gets grant for treatment of spinal muscular atrophy using ALK4:ACTIRiib antagonists
He added: “We also look forward to fully exploring povetacicept’s potential as a ‘pipeline-in-a-product’ and adding Alpine’s protein engineering and immunotherapy capabilities to Vertex’s toolbox.”
Acceleron Pharmaat preclinical studies have sspinal muscular atrophyist approach has demonstrated higher binding affinity and greater potency than single inhibitors of BAFF and APRIL.
Also announced on the same day as the acquisition was data from Alpine’s Phase I/II RUBY-3 trial (NCT05732402) investigating povetacicept in IgAN. After receiving the drug subcutaneously every four weeks at 80mg, patients had a 64.1% reduction from baseline in urine protein to creatinine ratio, indicating an improvement in proteinuria. Proteinuria is usually an indicator of kidney damage.
Alpine said it has had a successful end-of-Phase IIpovetacicepth the US Food and Drug Administration (FDA), opening up the development avenue to a Phase III trial, slated to startVertexe second half of 2024.
Also ramping up development activities in kidney disease is Novartis, which acquired assets – including Fabhalta (iptacopan) povetacicept TheIgANutics in a $3.2bn deal in August 2023. Fabhalta hit its interim endpoint in a Phase III trial last October, with Novartis seeking accelerated approval this year.proteinuriaProteinuria
Vertex’s acquisition adds to a bustling immunotherapy deal landscape US Food and Drug Administration (FDA)Sanofi and Bristol Myers Squibb also completing billion-dollar deals in the space recently.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。